Esclama,
K 1900,
K-1900,
K1900,
Naxogin,
Nimorazole,
Nitrimidazine,
Nulogyl,
Nimorazole,
6506-37-2,
Nitrimidazine,
Nimorazol,
Naxogin,
Nulogyl,
Esclama,
Naxofem,
Acterol,
Acterol forte,
Nimorazolo,
Sirledi,
4-(2-(5-Nitro-1H-imidazol-1-yl)ethyl)morpholine,
Nimorazolum,
K-1900,
N-2-Morpholinoethyl-5-nitroimidazole,
4-[2-(5-Nitroimidazol-1-yl)ethyl]morpholine,
Nimorazolo [DCIT],
1-(2-N-Morpholinylethyl)-5-nitroimidazole,
Nimorazol [INN-Spanish],
Nimorazolum [INN-Latin],
Morpholine, 4-[2-(5-nitro-1H-imidazol-1-yl)ethyl]-,
UNII-469ULX0H4G,
K 1900,
NSC 107524,
1-(beta-Morpholinoethyl)-5-nitroimidazole,
1-(N-p-Ethylmorpholine)-5-nitroimidazole,
EINECS 229-394-4,
4-(2-(5-Nitroimidazol-1-yl)ethyl)-morpholine,
BRN 0533758,
MLS002703984,
469ULX0H4G,
4-(2-(5-Nitroimidazol-1-yl)ethyl)morpholine,
Morpholine, 4-(2-(5-nitroimidazol-1-yl)ethyl)-,
4-[2-(5-Nitro-1H-imidazol-1-yl)ethyl]morpholine,
Morpholine, 4-(2-(5-nitro-1H-imidazol-1-yl)ethyl)-,
1-(.beta.-Morpholinoethyl)-5-nitroimidazole,
Morpholine, 4-[2-(5-nitroimidazol-1-yl)ethyl]-,
Nimorazole [BAN:INN],
Nimorazole [INN:BAN],
Nimorazole (INN),
Naxogin (TN),
AC1L2LGX,
DSSTox_CID_31584,
DSSTox_RID_97468,
DSSTox_GSID_57795,
SCHEMBL21836,
CHEMBL435966,
DTXSID1057795,
AOB6012,
CHEBI:134929,
MDJFHRLTPRPZLY-UHFFFAOYSA-N,
BCP11055,
Tox21_113897,
MFCD00866796,
NSC107524,
ZINC26167988,
AKOS022174968,
AN-2334,
API0016522,
CS-2854,
DB12172,
NSC-107524,
NCGC00261977-01,
AJ-82204,
AM807557,
AS-31120,
HY-16349,
K057,
LS-93226,
SC-16175,
SMR001570693,
CAS-6506-37-2,
WLN: T6N DOTJ A2- AT5N CNJ ENW,
AB0014002,
AX8144774,
FT-0710009,
4-[2-(5-nitro-1-imidazolyl)ethyl]morpholine,
4-[2-(5-Nitro-1-imidazolyl)ethyl]-morpholine,
A13091,
D07352,
506N372,
A834961,
4-[2-(5-Nitro-1H-imidazol-1-yl)ethyl]morpholine #,
Morpholine, 4-(2-(5-nitro-1H-imidazol-1-yl)ethyl)- (9CI),
Esclama|||K-1900|||Naxogin|||Nitrimidazine|||Nulogyl|||4-[2-(5-Nitroimidazol-1-yl)ethyl]morpholine,
C9H14N4O3,
CID23009,
C9-H14-N4-O3,
CS-W-00181,
K1900,
D009554,